The RANK-RANKL axis: an opportunity for drug repurposing in cancer?

Détails

ID Serval
serval:BIB_70A2BC9FF3FA
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The RANK-RANKL axis: an opportunity for drug repurposing in cancer?
Périodique
Clinical & translational oncology
Auteur⸱e⸱s
Peters S., Clézardin P., Márquez-Rodas I., Niepel D., Gedye C.
ISSN
1699-3055 (Electronic)
ISSN-L
1699-048X
Statut éditorial
Publié
Date de publication
08/2019
Peer-reviewed
Oui
Volume
21
Numéro
8
Pages
977-991
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Drug repurposing offers advantages over traditional drug development in terms of cost, speed and improved patient outcomes. The receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) inhibitor denosumab is approved for the prevention of skeletal-related events in patients with advanced malignancies involving bone, including solid tumours and multiple myeloma. Following improved understanding of the role of RANK/RANKL in cancer biology, denosumab has already been repurposed as a treatment for giant cell tumour of bone. Here, we review the role of RANK/RANKL in tumourigenesis, including effects on tumour initiation, progression and metastasis and consider the impact of RANK/RANKL on tumour immunology and immune evasion. Finally, we look briefly at ongoing trials and future opportunities for therapeutic synergy when combining denosumab with anti-cancer agents such as immune checkpoint inhibitors.
Mots-clé
Antineoplastic Agents/therapeutic use, Drug Repositioning, Humans, Neoplasms/drug therapy, Neoplasms/metabolism, Prognosis, RANK Ligand/metabolism, Receptor Activator of Nuclear Factor-kappa B/metabolism, Checkpoint, Denosumab, Immunotherapy, Osteoprotegerin, RANK, RANKL
Pubmed
Web of science
Open Access
Oui
Création de la notice
18/02/2019 11:49
Dernière modification de la notice
04/01/2020 6:17
Données d'usage